| Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|
| Buys | +190,672 | 100% | $10.60 | +$2,020,756 |
| Sells | ||||
| Net | +190,672 | 100% | +$2,020,756 |
| Security | Num Shares | Value | Price $ | Transaction Date | Ownership | Underlying Class | Underlying Amount |
|---|---|---|---|---|---|---|---|
| Common Stock | 747,887 | $8,107,095 | $10.84 | 18 Feb 2025 | Indirect | ||
| Stock Option (Right to Buy) | 15,963 | 12 Sep 2024 | Direct | Common Stock | |||
| Series A Convertible Preferred Stock | 0 | 16 Sep 2024 | By OrbiMed Private Investments VII, LP | Common Stock | |||
| Series B Convertible Preferred Stock | 0 | 16 Sep 2024 | By OrbiMed Private Investments VII, LP | Common Stock | |||
| Series C Convertible Preferred Stock | 0 | 16 Sep 2024 | By OrbiMed Genesis Master Fund, L.P. | Common Stock |
| Sym | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|